The underlying principle behind ROSALIND is that cancers are diseases of cell signaling and any hope of sustained remission is dependent on therapies that restore normal cell signaling to regulate cell division and apoptosis.
While access to high-quality cancer gene mutation profiling continues to evolve, personalized cancer therapy has been a big data problem. For example, the number of unique single, double, and triple drug combinations from just 150 cancer drugs would be in excess of 540,000. This is simply too many potential therapies for any physician or group of physicians to evaluate. ROSALIND addresses this big data problem.
Note: The simulation output drug combinations only include drugs currently approved or in clinical trials.